Abstract

Simple SummaryProstate Cancer is one of the main threats to men’s health. Its accurate diagnosis is crucial to properly treat patients depending on the cancer’s level of aggressiveness. Tumor risk-stratification is still a challenging task due to the difficulties met during the reading of multi-parametric Magnetic Resonance Images. Artificial Intelligence models may help radiologists in staging the aggressiveness of the equivocal lesions, reducing inter-observer variability and evaluation time. However, these algorithms need many high-quality images to work efficiently, bringing up overfitting and lack of standardization and reproducibility as emerging issues to be addressed. This study attempts to illustrate the state of the art of current research of Artificial Intelligence methods to stratify prostate cancer for its clinical significance suggesting how widespread use of public databases could be a possible solution to these issues.Many efforts have been carried out for the standardization of multiparametric Magnetic Resonance (mp-MR) images evaluation to detect Prostate Cancer (PCa), and specifically to differentiate levels of aggressiveness, a crucial aspect for clinical decision-making. Prostate Imaging—Reporting and Data System (PI-RADS) has contributed noteworthily to this aim. Nevertheless, as pointed out by the European Association of Urology (EAU 2020), the PI-RADS still has limitations mainly due to the moderate inter-reader reproducibility of mp-MRI. In recent years, many aspects in the diagnosis of cancer have taken advantage of the use of Artificial Intelligence (AI) such as detection, segmentation of organs and/or lesions, and characterization. Here a focus on AI as a potentially important tool for the aim of standardization and reproducibility in the characterization of PCa by mp-MRI is reported. AI includes methods such as Machine Learning and Deep learning techniques that have shown to be successful in classifying mp-MR images, with similar performances obtained by radiologists. Nevertheless, they perform differently depending on the acquisition system and protocol used. Besides, these methods need a large number of samples that cover most of the variability of the lesion aspect and zone to avoid overfitting. The use of publicly available datasets could improve AI performance to achieve a higher level of generalizability, exploiting large numbers of cases and a big range of variability in the images. Here we explore the promise and the advantages, as well as emphasizing the pitfall and the warnings, outlined in some recent studies that attempted to classify clinically significant PCa and indolent lesions using AI methods. Specifically, we focus on the overfitting issue due to the scarcity of data and the lack of standardization and reproducibility in every step of the mp-MR image acquisition and the classifier implementation. In the end, we point out that a solution can be found in the use of publicly available datasets, whose usage has already been promoted by some important initiatives. Our future perspective is that AI models may become reliable tools for clinicians in PCa diagnosis, reducing inter-observer variability and evaluation time.

Highlights

  • Prostate Cancer (PCa) is one of the most common types of cancer among men, causing thousands of deaths every year worldwide [1]

  • When using the AUC metric, almost all the Artificial Intelligence (AI) models achieved a higher performance with respect to the Prostate Imaging—Reporting and Data System (PI-RADS)

  • In the case of specificity and sensitivity for the training set, there is a negative correlation between samples and performance, but this could depend on many other factors, such as the model implemented or the quality of the data

Read more

Summary

Introduction

Prostate Cancer (PCa) is one of the most common types of cancer among men, causing thousands of deaths every year worldwide [1]. Men without cancer often undergo unnecessary systematic prostate biopsies with a potential risk of complications (mainly infections), and clinically indolent cancers are often detected, but biologically aggressive cancers are sometimes missed [2]. Mp-MRI is an essential tool for a targeted prostate biopsy that significantly increases the detection of clinically significant PCa in different settings [4], for surgical planning of nerve sparing approach [5], and for risk assessment during active surveillance protocol [6]. PI-RADS version 2.1 [7] is a standard for reading mp-MR images to risk-stratify PCa by assigning a score to the suspected lesions index that ranges from 1 to 5, from benign to malign PCa, depending on the lesion’s aspect and localization [8]. We will discuss the recent achievement and what could be improved in PCa characterization using Artificial Intelligence (AI) methods

AI in PCa Characterization
Overfitting
Standardization and Reproducibility
The Role of Public Databases
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call